A Systematic Review of Literature: TNF‐α Blockers and JAK Inhibitors for the Treatment of Stevens‐Johnson Syndrome, Toxic Epidermal Necrolysis, and Severe Forms of Erythema Multiforme Authors: Sadaf Salehi, Pooneh Torabi, Mahsa Abbaspour, Nima Hajizadeh, Sara Sadeghi, Alireza Jafarzadeh, Azadeh Goodarzi Published: 2026 ABSTRACT ABSTRACTBackground and AimsStevens‐Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and erythema multiforme major (EM major) are severe dermatologic conditions characterized by varying degrees of skin detachment and involvement of mucosal membranes, often triggered by drug reactions or infections. The management of these conditions poses a significant challenge due to the potential for rapid progression to life‐threatening complications. Recently, emerging therapeutic approaches such as Tumor Necrosis Factor‐alpha (TNF‐α) blockers and Janus Kinase (JAK) inhibitors have shown promise in regulating the dysregulated immune response implicated in these disorders. A comprehensive literature review was conducted to evaluate the efficacy and safety of TNF‐α blockers and JAK inhibitors in treating SJS, TEN, and EM.MethodsA systematic review was conducted according to PRISMA guidelines. A comprehensive literature search was performed in PubMed, Scopus, Embase, Web of Science, and Google Scholar, up to September 5, 2025, on JAK inhibitors and TNF inhibitors in treating SJS, TEN, or EM major.ResultsThe current review studies 82 articles (748 patients), including case reports, cohort studies, and clinical trials. Various JAK inhibitors and TNF inhibitors, such as tofacitinib, etanercept, adalimumab, and infliximab, were assessed regarding effectiveness in treating SJS/TEN and EM. Notably, some cases demonstrated a rapid response to these inhibitors, resulting in faster re‐epithelialization and a reduction in the severity of lesions.ConclusionTNF‐α blockers like infliximab and etanercept show promise for patients unresponsive to standard treatments, shortening acute phases, reducing hospitalization, and mortality rates, and enhancing healing. Further research, especially registry‐based studies, is crucial. Healthcare practitioners are advised to exercise caution and reserve novel drugs for managing hypersensitivity reactions.Keywords: erythema multiforme major, JAK inhibitors, Janus Kinase inhibitors, severe cutaneous adverse reaction, SJS, Systematic Review, TEN, TNF‐α inhibitor, Toxic epidermal necrolysis Abbreviations body surface area intravenous immunoglobin Janus kinas rheumatoid arthritis severe cutaneous adverse reactions Steven Johnson Syndrome toxic epidermal necrolysis tumor necrosis factor tyrosine kinase 2 Introduction Stevens ‐ Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are potentially life‐threatening dermatologic emergencies characterized by extensive epidermal necrolysis and shedding [1]. Such conditions generally occur 4–28 days after exposure to certain medications or viruses [2]. They are considered the same in terms of pathophysiology and different in terms of involvement of body surface area (BSA). The involved BSA in SJS and TEN are below 10% and over 30%, respectively. A 10%–30% BSA involvement is known as SJS/TEN overlap [1]. Another differential diagnosis of the SJS/TEN spectrum is the erythema multiforme (EM) which is usually a mild reaction to certain medications or viruses such as herpes simplex virus [3]. EM in most cases is controlled by supportive care and topical treatments [2]. However, EM has a severe form named EM major which resembles SJS and TEN in severity and clinical progression. The current therapeutic approach consists of immediate cessation of causative medication, supporting treatments, wound care, and controversial medical agents which could be used to cease these reaction pathways [2, 4]. Currently, systemic corticosteroids, intravenous immunoglobulins (IVIGs), and other immunomodulators including cyclosporine are the most common medications used for TEN/SJS and EM major. There are also other classes of medications that have been used in solo or combination in some cases [5, 6]. Due to the severity, unpredictable course, and high mortality rate, many patients with such conditions need immediate admission to intensive care units for multidisciplinary care. Despite the widespread use of systemic glucocorticoids, cyclosporine, and intravenous immunoglobulin (IVIG) in the management of SJS/TEN and EM major, the evidence supporting these therapies remains heterogeneous and, in some cases, controversial [4]. Their clinical use may also be limited by variable efficacy, potential adverse effects such as secondary infections, nephrotoxicity, and other treatment‐related complications, as well as financial burden and restricted accessibility in some healthcare settings [5, 6]. Given these limitations and the immune‐mediated pathophysiology of SCARs, emerging targeted therapies such as TNF‐α blockers and JAK inhibitors have gained increasing attention. Therefore, a comprehensive systematic review of these newer immunomodulatory agents is needed to summarize the available evidence and evaluate their potential role in addressing the shortcomings of conventional treatment approaches. The main histopathologic features of the TEN/SJS spectrum include the separation of dermal and epidermal layers, necrosis of the epidermis, and apoptosis of keratinocytes. These changes are the result of immune system over‐activation through different T‐cell‐related immunologic pathways [7, 8]; cytokines such as IL‐6, IL‐15, TNF‐α, and so forth are elevated both in the mucocutaneous bullae and serum of patients with TEN/SJS [9]. Meanwhile, some studies demonstrated a positive correlation between a greater amount of cytokines like IL‐15 and the severity of the disease [10]. Considering the pathophysiology, certain types of medications could be used to control the progression of such conditions; two therapeutic target groups are the Janus kinase (JAK) family and tumor necrosis factor (TNF). JAK family consists of JAK1, JAK2, JAK3, and Tyrosine kinase 2 (TYK2) enzymes, involved in the JAK/signal transducer and activator of transcription proteins (JAK‐STAT) pathway in lymphocytes. Consequently, JAK inhibitors can halt the JAK‐STAT pathway and lymphocyte activity [10]. This effect prompted studies exploring JAK inhibitors as therapeutic options for immune‐mediated conditions such as myelofibrosis and rheumatoid arthritis (RA) [10, 11]. On the other hand, TNF, formerly known as TNF‐α, is a cytokine involved in cell death by direct cytotoxicity and induction of apoptosis [12]. Inhibition of TNF is an effective treatment in non‐infectious inflammatory conditions, such as Crohn's disease, RA, and psoriasis [13]. Strong TNF expression in TEN lesions has encouraged studying TNF inhibitors as potentially effective treatments and resulted in promising outcomes [12, 14, 15]. In the end, due to the potentially life‐threatening manifestations of SJS and TEN, immune‐mediated pathophysiology, and a growing use of JAK and TNF inhibitors in immune‐mediated conditions, we conducted a comprehensive systematic review of JAK/TNF inhibitors in the treatment of TEN/SJS, or EM major. This review intends to summarize the available evidence and support clinical decision‐making. Methods and Materials The current systematic review was performed according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta‐Analyses) statement; eligible cases were identified by the population‐intervention‐comparator‐outcomes‐study design (PICOS) framework: Population, humans experiencing hypersensitivity reactions of TEN, SJS, and severe cases of EM. Intervention, using any medications in the class of JAK inhibitors or TNF blockers to control cutaneous manifestations of those conditions. Comparator, patients with the same hypersensitivity reactions treated with conventional therapeutic regimens such as corticosteroids, IVIG, or other immunomodulator medications. Outcomes, any differences in the time of hospitalization/re‐epithelialization, side effects, complications, and mortality rate, and so forth. Search Strategy A systematic review was conducted according to PRISMA guidelines (Figure 1). A comprehensive literature search was performed in PubMed, Scopus, Embase, Web of Science, and Google Scholar, up to September 5, 2025. PRISMA 2020 flow diagram for systematic review. The search strategy was developed using combinations of keywords and Boolean operators (AND, OR). The main search terms included “Stevens‐Johnson syndrome,” “toxic epidermal necrolysis,” “erythema multiforme major,” “TNF inhibitors,” “etanercept,” “adalimumab,” “infliximab,” “JAK inhibitors,” and “tofacitinib.” These terms were combined using appropriate Boolean operators to optimize the search strategy (Table 1). Table 1Search strategies for databases.PubMed(“Toxic epidermal necrolysis “ OR “TEN” OR “ Stevens‐Johnson syndrome “ OR “SJS” OR “ TEN/SJS “ OR “Erythema multiforme major” OR “ Erythema multiforme”) AND (“TNF‐α blockers “ OR “ TNF‐α inhibitors” OR “ JAK inhibitors “ OR “ Tyrosine kinase 2 inhibitors “ OR “ TYK 2 inhibitors “ OR “Adalimumab” OR “ Etanercept” OR “ Infliximab” OR “certolizumab pegol” OR “golimumab” OR “tofacitinib” OR “baricitinib” OR “ruxolitinib” OR “upadacitinib” OR “fedratinib” OR “abrocitinib” OR “ritlecitinib” OR “deucravacitinib”)Scopus(TITLE‐ABS‐KEY(“Toxic epidermal necrolysis “ OR “TEN” OR “ Stevens‐Johnson syndrome “ OR “SJS” OR “ TEN/SJS “ OR “Erythema multiforme major” OR “ Erythema multiforme”)ANDTITLE‐ABS‐KEY(“TNF‐α blockers “ OR “ TNF‐α inhibitors” OR “ JAK inhibitors “ OR “ Tyrosine kinase 2 inhibitors “ OR “ TYK 2 inhibitors “ OR “Adalimumab” OR “ Etanercept” OR “ Infliximab” OR “certolizumab pegol” OR “golimumab” OR “tofacitinib” OR “baricitinib” OR “ruxolitinib” OR “upadacitinib” OR “fedratinib” OR “abrocitinib” OR “ritlecitinib” OR “deucravacitinib”))Web of Science TS = (“Toxic epidermal necrolysis “ OR “TEN” OR “ Stevens‐Johnson syndrome “ OR “SJS” OR “ TEN/SJS “ OR “Erythema multiforme major” OR “ Erythema multiforme”) AND TS = (“TNF‐α blockers “ OR “ TNF‐α inhibitors” OR “ JAK inhibitors “ OR “ Tyrosine kinase 2 inhibitors “ OR “ TYK 2 inhibitors “ OR “Adalimumab” OR “ Etanercept” OR “ Infliximab” OR “certolizumab pegol” OR “golimumab” OR “tofacitinib” OR “baricitinib” OR “ruxolitinib” OR “upadacitinib” OR “fedratinib” OR “abrocitinib” OR “ritlecitinib” OR “deucravacitinib”) Search strategies for databases. TS = (“Toxic epidermal necrolysis “ OR “TEN” OR “ Stevens‐Johnson syndrome “ OR “SJS” OR “ TEN/SJS “ OR “Erythema multiforme major” OR “ Erythema multiforme”) AND TS = (“TNF‐α blockers “ OR “ TNF‐α inhibitors” OR “ JAK inhibitors “ OR “ Tyrosine kinase 2 inhibitors “ OR “ TYK 2 inhibitors “ OR “Adalimumab” OR “ Etanercept” OR “ Infliximab” OR “certolizumab pegol” OR “golimumab” OR “tofacitinib” OR “baricitinib” OR “ruxolitinib” OR “upadacitinib” OR “fedratinib” OR “abrocitinib” OR “ritlecitinib” OR “deucravacitinib”) Filters were applied where applicable, including limiting results to human studies and English‐language publications. Literature Screening For the screening process, EndNote software, version 20, was utilized. Before screening 857 duplicates were detected by EndNote and removed. During the screening, two investigators reviewed all the literature by reading titles and abstracts to ensure their quality was included in data extraction, and the remaining duplicates were removed manually. Disagreements were resolved with a group discussion or the consensus of the corresponding investigator. In the last phase of screening, full texts were reviewed by three investigators, and 82 publications were selected for data extraction. In addition to database searching, the reference lists of included studies were manually screened to identify any additional relevant articles. Inclusion and Exclusion Criteria The inclusion criteria comprised English articles about the effect of JAKi or TNF‐α blocker medications on mucocutaneous manifestations of TEN/SJS or EM major. Exclusion criteria were reviews, investigational studies (animal, in‐vitro/ex‐vivo), treating TEN/SJS and EM major with medications other than JAK inhibitors or TNF‐α blockers, and studies considering the use of these medications in other medical conditions. Data Extraction Extracted data include (i) study characteristics: name of the authors, year, design of the study, county (ii) patients’ characteristics: age, gender, sample size, past medical history, the severity of the reactions and the involvement percentage, (iii) details on the treatment: duration between the onset of lesions and first dose of JAKi/TNF blockers, other treatments before or alongside JAKi/TNF blockers, duration of treatment, route of administration, and number of doses, and (IV) results: duration of hospitalization, side effects, complications, time to re‐epithelialization, and possible relapses. Microsoft Word software, version 16.56, was utilized for data extraction. Three investigators were involved in the data collection process, independently. Some main features of extracted data have been summarized in Tables 2, 3, 4, 5, 6, 7. Table 2Summary of case reports/series on etanercept therapy of SCARS.Author, yearSex, ageSeverity and involvementComorbidityOther treatmentTime to treat (days)Side effectsRe‐epithelialization time (days)Natsis, 2022F, 2060%NANANANA30Ridha, 2021M, 7654%HTN, Hailey Hailey, RCC & nephrectomyNo1NA4Faris, 2021F, 7190NANo9SIRS, AKI, electrolyte imbalanceDeath despite resolutions of cutaneous manifestationsF, 74> 90NAPrior cyclosporine20AF, bleedingDeath despite resolutions of cutaneous manifestationsF, 40> 40%NAPrednisolone, cyclosporine3arrestDeath despite resolutions of cutaneous manifestationsFamularo, 2007M, 5960%HTN, IHD, CKDPrior and alongside prednisolone and cyclosporine4died of DIC at day 10death despite complete skin healing on day 6Sadighha, 2009F, 56NANAPrednisolone1NA18Didona, 2015NASCORTEN 2‐6NANoNANo7–20 (median 8.5)Paradisi, 20146 F, 4 M/61.6SCORTEN 6Cerebral neoplasmNo< = 3No12SCORTEN 3BronchopneumoniaNo< = 3No8SCORTEN 2Systematic lupus erythematousNo< = 3No8SCORTEN 3Pemphigus vulgarisNo< = 3No12SCORTEN 4BronchopneumoniaNo< = 3No8SCORTEN 5Cerebral neoplasmNo< = 3No7SCORTEN 2NoNo< = 3No8SCORTEN 6Cerebral metastasis of breast cancerNo< = 3No20SCORTEN 2ICHNo< = 3No9SCORTEN 3PeriarthritisNo< = 3No9Yardanova, 2022F, 59NAMalignant melanomaPrior IVIG, prednisoloneNANoNAParadisi, 2020NALowest SCORTEN:2, 5 patients with SCORTEN > = 5NANoNANo2 deaths due to other causes, 15 prompt response versus 10/17 expected mortality rateGavigan, 2018F, 1125%NAPrior Methylprednisolone followed by cyclosporine2NANALi, 2020F, 25Almost 100%NAIVIG, methylprednisolone0NANAde Perosanz, 2021F, 7815%–20%Hypothyroidism/Dyspepsia/idiopathic pulmonary fibrosisNo0No3 months to complete resolutionSingh, 2022F, 4725%differentiated carcinoma of urothelial originPrior IVIG treatments3NA5 daysWang, 2019F, 3320%acute upper respiratory tract infectionPrior and alongside Methylprednisolone, IVIG5No15 daysGao, 2020M, 60> 30%, SCORTEN 3HTN/ocular lymphedemaPrior Methylprednisolone and IVIG7No21 daysDidona, 2016NA, 60≥ 30%, SCORTEN 3Pemphigus vulgarisNo0NoNAAndrades, 2021F, 57NANoCombination therapy with IVIG, methylprednisolone and cyclosporineNANoa few weeksOsawa, 2022M, 70SCORTEN 4metastatic prostate cancerPrior IVIG and methylprednisolone5No42 daysBakir, 2021F, 49> 30%, SCORTEN 2NANo0No22 daysGubinelli, 2009F, 59> 30%Brain tumor/epilepsyPrior methylprednisolone10No20 daysNapolitano, 2013F, 67.3> 30%case 1&2: Systemic lupus erythematousCase 3: methylprednisolone0No8–12 daysChoi, 2022M, 46> 90%, SCORTEN 3ascending aortic dissectionPrior methylprednisolone and alongside dexamethasone1No23 daysChahal, 2018F, 1930%, SCORTEN 1NoNo0No8 daysLee, 2013M, 3240%, SCORTEN 1HIVAlongside methylprednisolone1No14 daysZander, 2021M, 1390%NoPrior Methylprednisolone4No13 daysVural, 2013F, 89NAPsoriasisNo0NoNASeminari‐ Vidal, 2017NANANAPrior corticosteroids, IVIGNANANANikitina, 2023F, 50 < 10% SCORTEN 1□ 2 NAPrior and alongside methylprednisolone10No5 daysEstebanez, 2020M, 830%,Post‐traumatic stress disorderIVIG, Corticosteroids3NA16 daysGhai, 2023M, 44> 50%Diabetes mellitus type 2Prior methylprednisoloneNANADeath due to multiorgan failureEliades, 2020M, 480%NANo4NA16F, 780%NANo4NA13F, 1830%NANo1NADisease progress was halted before any denudation OccurredF, 750%NANo1NA10Chong, 2017M, 77SCORTEN 2DM, HTN, CAD, Hyperlipidemia,No0NA5Abbreviations: AF, atrial fibrillation; AKI, acute kidney injury; CAD, coronary artery disease; CKD, chronic kidney disease; DIC, disseminated intravascular coagulation; DM, diabetes mellitus; EM, erythema multiforme; HIV, human immunodeficiency virus; HTN, hypertension; ICH, intracranial hemorrhage; ICU, intensive care unit; IHD, ischemic heart disease; IVIG, intravenous immunoglobulin; LOS, length of stay; PIH, post‐inflammatory hyperpigmentation; RCC, renal cell carcinoma; SIRS, systemic inflammatory response syndrome; SJS, Stevens‐Johnson syndrome; TEN, toxic epidermal necrolysis. Summary of case reports/series on etanercept therapy of SCARS. < 10% SCORTEN 1□ 2 Abbreviations: AF, atrial fibrillation; AKI, acute kidney injury; CAD, coronary artery disease; CKD, chronic kidney disease; DIC, disseminated intravascular coagulation; DM, diabetes mellitus; EM, erythema multiforme; HIV, human immunodeficiency virus; HTN, hypertension; ICH, intracranial hemorrhage; ICU, intensive care unit; IHD, ischemic heart disease; IVIG, intravenous immunoglobulin; LOS, length of stay; PIH, post‐inflammatory hyperpigmentation; RCC, renal cell carcinoma; SIRS, systemic inflammatory response syndrome; SJS, Stevens‐Johnson syndrome; TEN, toxic epidermal necrolysis. Table 3Summary of interventional studies on etanercept therapy.Author, yearN of casesSex, ageSCORTEN/involvementTime to treatCase resultsControl treatmentControl resultsOther resultsDidona, 201930NA, 18‐90NANA 2 patients died of other causes Observed death: 2 Expected: 10 ——Median 8.5 days re‐epithelialization, the comparison between observed versus expected deaths was statistically significant (p = 0.012)Sivagnanalingam, 202224(8 cases)NA, NANANASMR 0.00NASMR 0.56LOS in SJS and overlap patients differed significantly between the 2 groupsC.H. Pham, 20191338.5% M, 44.8 ± 21.1 Case: 3 Control: 2 Case: 5.2 Control: 2.7 SMR: 0.44 Mortality 15.4%, ICU days: 6.9, LOS: 9.8, infectious: 38.5% NAMortality 10%, ICU days: 15.1, LOS: 16.4, infectious:57.5%no significant difference in mortality, ICU days, length‐of‐stay or infections.Tian, 202225 (14 cases)NA, 11‐77NANALOS 13.5 daysIVIG and corticosteroids onlyLOS 19.0 daysShorter hospitalization and less exposure to corticosteroids in combination therapyDreyer, 202122 (13 cases)NA, NA Case: 2.15 (30%) Control: 2.44 (23%) NANo mortality, re‐epithelialization days 8.1 daysIVIG3 mortalitiestreatment with etanercept may be less effective if IVIG and/or steroids are given prior to etanercept compared to when etanercept is given quicklyWorswick, 202030(21 cases)NA, NANANA Expected mortality 17.5% Actual mortality: 0% Either supportive care or IVIGExpected morality 20.8 versus actual mortality 30.3%Lower SMR and actual mortality rate and relatively rapid response in etanercept groupPham, 201813 casesNA, NA Case: 3 (54.3%) Control: 2 (46.3%) 5.7 days (vs. 2.6) ICU days: 6.9, LOS:9.8 Infection: 38.5% Mortality: 15.4% NA ICU days: 15.1 LOS: 16.4 Infection: 57.5% Mortality: 10% fewer ICU days, shorter total LOS and fewer infectious complications. There was no significant difference in mortality rateS. T. Ao, 202225(15 cases)56% M, 40.20 ± 18.28NANA Re‐epithelialization: 12 LOS: 12 Only methylprednisolone Re‐ epithelialization:16 LOS: 14 the combination therapy significantly shortened the course of the initial steroid treatment and the duration of the acute stage, hospitalization stay, and skin re‐epithelialization.Wang, 201896NANANA Predicted mortality: 17.7% Mortality: 8.3% Median skin healing time: 14 days Gastrointestinal bleeding: 2.6% Traditional corticosteroids Median skin healing time: 19 days Gastrointestinal bleeding: 18.2% Decreased SCORTEN‐based mortality rate, skin healing time, GI bleeding) and TNF‐α and granulising secretions as mortality predictors in blister fluids and plasma of the etanercept groupOginezawa, 20234NAMean SCORTEN 2NA1 patient emerged sepsisNo control groups. Etanercept combination therapy was tested on priorly corticosteroid resistant patients—Recovery: 3.5 days, Re‐epithelialization: 18.5 daysZhang, 2022242NANANA Mortality: 0% SMR: 0 Median skin healing time: 12 (8.5–14) Lower adverse events of gastrointestinal bleeding Corticosteroids monotherapy Mortality: 6.63% SMR: 0.71 Median skin healing time: 13 [10, 11, 12, 13, 14, 15, 16, 17, 18] Etanercept combination therapy reduces SMR, actual mortality rate, and skin healing time as well as adverse events such as gastrointestinal bleedingCorticosteroids+ IVIG Mortality: 4.76% SMR: 0.30 Median skin healing time: 13.5 (10–19.5) Abbreviations: EM, erythema multiforme; ICU, intensive care unit; IVIG, Intravenous immunoglobulin; LOS, length of stay; SJS, Stevens‐Johnson syndrome; SMR, Standardized mortality ratio; TEN, toxic epidermal necrolysis. Summary of interventional studies on etanercept therapy. 2 patients died of other causes Observed death: 2 Expected: 10 Case: 3 Control: 2 Case: 5.2 Control: 2.7 SMR: 0.44 Mortality 15.4%, ICU days: 6.9, LOS: 9.8, infectious: 38.5% Case: 2.15 (30%) Control: 2.44 (23%) Expected mortality 17.5% Actual mortality: 0% Case: 3 (54.3%) Control: 2 (46.3%) ICU days: 6.9, LOS:9.8 Infection: 38.5% Mortality: 15.4% ICU days: 15.1 LOS: 16.4 Infection: 57.5% Mortality: 10% Re‐epithelialization: 12 LOS: 12 Re‐ epithelialization:16 LOS: 14 Predicted mortality: 17.7% Mortality: 8.3% Median skin healing time: 14 days Gastrointestinal bleeding: 2.6% Median skin healing time: 19 days Gastrointestinal bleeding: 18.2% Mortality: 0% SMR: 0 Median skin healing time: 12 (8.5–14) Lower adverse events of gastrointestinal bleeding Mortality: 6.63% SMR: 0.71 Median skin healing time: 13 [10, 11, 12, 13, 14, 15, 16, 17, 18] Mortality: 4.76% SMR: 0.30 Median skin healing time: 13.5 (10–19.5) Abbreviations: EM, erythema multiforme; ICU, intensive care unit; IVIG, Intravenous immunoglobulin; LOS, length of stay; SJS, Stevens‐Johnson syndrome; SMR, Standardized mortality ratio; TEN, toxic epidermal necrolysis. Table 4Efficacy and safety of etanercept for erythema multiforme major treatment.Author, yearSex, ageSeverity and involvementComorbidityOther treatmentTime to treatSide effectsRe‐epithelialization time (days)Trujillo‐Trujillo, 2018M, 45NANoPrior methylprednisolone5 daysNA2 daysLing, 2017F, 7380%, SCORTEN 2Hypertension, gastric ulcerNoNANo14 daysHuang, 2023F, 5NANoNo3 daysNoNA Efficacy and safety of etanercept for erythema multiforme major treatment. Table 5Efficacy and study characteristics data on monotherapy with infliximab.References/YearPtAge (Mean)/SexComorbiditiesPrior treatmentsDiagnosisSCORTEN/BSATime to treatmentOutcome/Side EffectsTime to re‐epithelializationHunger 2005 [12]169/FHTN, Psoriasis, HypothyroidismNoTEN2/ > 30%3 daysComplete recovery5 daysWojtkiewicz 2008 [4]117/FNoDexamethasone, IVIGTENNA/80%9 daysComplete Recovery & post‐inflammatory hyperpigmentation (PIH)12 daysScott‐Lang 2011 [6]17/MAutism, EpilepsyIVIGTENNA2Complete Recovery7 daysWorsnop 2012 [7]132/FNoIVIGTEN2/ > 30%3 daysComplete Recovery & PIH9 daysWallenborn 2017 [9]144/MNoPrednisoloneTEN2/80%NAComplete Recovery & PIH28 daysAl‐Shouli, 2005167/MCHD, DM, gout, HTN, obesity, hyperlipidemia,PrednisoloneTENNA/40‐50%10Complete recovery‘10Seminario‐ Vidal, 20171NANAHigh dose steroidsTEN/GVHDNANAComplete recoveryNAZarate, 2013276/MNANoTEN2/100%NAComplete Recovery920/FHIVmethylprednisoloneTEN2/100%NAComplete Recovery7Chafranska 2019 [11]17/MNoNoTENNA/30%5 daysResolution in 1 month and PIH3Kreft 2010 [5]131/MDisk herniationPrednisoloneTENNA/ > 50%NAComplete Recovery & PIH35 daysFischer 2002 [1]156/FHTNNoTENNA/35%4 daysComplete RecoveryWithin 28 daysAbbreviations: AKI, acute kidney injury; CHD, Coronary Heart Disease; CKD, Chronic kidney disease; DM, Diabetes mellitus; EM, erythema multiforme; GVHD, Graft versus host disease; HIV, Human immunodeficiency virus; HTN, Hypertension; IHD, Ischemic heart disease; IVIG, Intravenous immunoglobulin; PIH, post‐inflammatory hyperpigmentation; SJS, Stevens‐Johnson syndrome; TEN, toxic epidermal necrolysis; Efficacy and study characteristics data on monotherapy with infliximab. Abbreviations: AKI, acute kidney injury; CHD, Coronary Heart Disease; CKD, Chronic kidney disease; DM, Diabetes mellitus; EM, erythema multiforme; GVHD, Graft versus host disease; HIV, Human immunodeficiency virus; HTN, Hypertension; IHD, Ischemic heart disease; IVIG, Intravenous immunoglobulin; PIH, post‐inflammatory hyperpigmentation; SJS, Stevens‐Johnson syndrome; TEN, toxic epidermal necrolysis; Table 6Efficacy and study characteristics data on combination therapy with infliximab.References/YearPtAge (Mean)/SexComorbiditiesDiagnosisSCORTEN/BSAOther Therapeutic modalitiesTime to Treatment (day)Outcome/Side EffectsTime to Re‐epithelialization (day)Meiss 2007 [3]3 42 1M2F NoOverlap TEN & acute generalized exanthematous pustulosisNAmethylprednisoloneNAComplete Recovery6‐14 daysKreft 2014 [8]111/FNoTENNAIVIG9 daysLarge extent of re‐epithelialization14 daysJiang 2018 [10]136/FVogt‐Koyanagi‐Harada syndrome & secondary glaucomaTEN35%methylprednisolone5 daysComplete Recovery7 daysPlant 2020 [12]132/FAlopecia totalisTENNAIVIGNAresolution of long‐term complications as well as EruptionsNAZarate, 2013251/FNATEN4/100%methylprednisoloneNARecovery despite PTE, bacteremia717/FepilepsyTEN3/50%IVIGNARecovery despite bacteremia16Gaitanis, 20123Mean 72.6/MHTN, AF, DM, BPH, and heart failure in casesTEN 4/20% 3/40% 4/30% High‐dose IVIG and corticosteroids0Recovery in two cases, one case passed away due to sepsis and multi organ failure21, 22 daysAbbreviations: AF, atrial fibrillation; BPH, Benign prostatic hyperplasia; CKD, chronic kidney disease; DM, diabetes mellitus; EM, erythema multiforme; HTN, hypertension; IHD, ischemic heart disease; IVIG, intravenous immunoglobulin; PIH, post‐inflammatory hyperpigmentation; SJS, Stevens‐Johnson syndrome; TEN, toxic epidermal necrolysis. Efficacy and study characteristics data on combination therapy with infliximab. 42 1M2F 4/20% 3/40% 4/30% Abbreviations: AF, atrial fibrillation; BPH, Benign prostatic hyperplasia; CKD, chronic kidney disease; DM, diabetes mellitus; EM, erythema multiforme; HTN, hypertension; IHD, ischemic heart disease; IVIG, intravenous immunoglobulin; PIH, post‐inflammatory hyperpigmentation; SJS, Stevens‐Johnson syndrome; TEN, toxic epidermal necrolysis. Table 7Efficacy and safety of different therapeutic regimens on recurrent erythema multiforme cases.Author, yearComorbilityDrug and dosagePrior treatmentsFinal resultFollow up durationNKonda, 2022NATofacitinib 5 mg BDCorticosteroids, cyclosporine, dapsone, tacrolimus, anakinra, rituximab, adalimumab, apremilast, mycophenolate mofetil, and intravenous immunoglobulin (IVIG)Complete remission without side effects2 years1Csiky‐Sessoms, 2019NATofacitinib 5 mg BDSystemic corticosteroids, mycophenolic acid, famciclovir, topical tacrolimus, thalidomide, apremilast and etanerceptlesions improved but relapsed after drug discontinuation8 months1Damsky, 2016papillary thyroid cancer in remission,Tofacitinib 5 mg BDTopical corticosteroids, dapsone, valacyclovir, cyclosporine, azathioprine, mycophenolate mofetil, or methotrexate did not permit tapering of prednisone to less than 20 mg/d without a flare upComplete remission8 months1Murphy, 2021NoTofacitinib 100 mg BD, upadacitinib 15 mg daily was added in one caseNoComplete remission with titration of tofacitinib in all of the casesNA4Drahy, 2018NALenalidomide 20 mg dailySystemic corticosteroids, valacyclovir, and thalidomide at low and high dosesPartial remission5 months3Lenalidomide 10 mg dailyComplete remission1 monthLenalidomide 10 mg dailyComplete remission1 monthChen, 2008NAThalidomide 100 mg dailyOral corticosteroids and topical agents, empiric valacyclovirComplete remission2 weeks1Moisson, 1992Reiter syndrome in one of the casesThalidomide 100 mg dailySteroid. Acyclovir, hydroxychloroquine, dapsone, high‐dose IVIG, colchicine and potassium iodideComplete remission in one of the cases, and only effective on oral ulcers in the other case, Abnormality in EMG and neuropathy in both cases6 months2Bahmer, 1982NAThalidomide 200 mg then 100 mg dailyNAComplete remission with 100 mg daily maintenance doseNA1Cherouati, 1996NAThalidomide 100 mg dailyAcyclovir, PrednisoloneLesions disappeared within a week and remission was maintained with low dose‐treatment.NA26Varma, 2006PsoriasisThalidomide 100 mg dailyDapsonePsoriasis exacerbationTreatment stopped within 2 weeks due to psoriasis exacerbation1Roux, 2021NAThalidomide 50‐100 mgResistant to at least one drug (not mentioned)Complete remission in 6 months in 2/3 of the cases despite asthenia (46%), and neuropathy (40%)6 months35Baillis, 2017NAAdalimumab 40 mg/weekNoComplete remission6 months1Abbreviations: EMG, Electromyography; IVIG, intravenous immunoglobulin. Efficacy and safety of different therapeutic regimens on recurrent erythema multiforme cases. Abbreviations: EMG, Electromyography; IVIG, intravenous immunoglobulin. Bias Assessment and Quality Evaluation The NIH quality assessment tool was utilized for the bias assessment of case reports and case series [16]. The methodological quality and synthesis of the case reports and case series, suggested by Murad et al., 2018 [17] was also used for these studies. Newcastle‐Ottawa Quality assessment scale for non‐randomized studies as well as the Cochrane risk of bias tool was also used for other studies. The risk of bias assessment was conducted independently by multiple investigators. Disagreements were resolved through discussion and consensus, with involvement of a third reviewer when necessary. Data Analysis Results were systematically reviewed and described. Microsoft Word software, version 16.56, was used in the process. Descriptive summary measures were calculated for outcomes that were reported with sufficient consistency across studies. For continuous outcomes such as re‐epithelialization time, crude averages were derived from the reported subgroup‐level means or medians. Formal pooled analyses for response rate and mortality were not performed across all TNF‐α blocker studies because of substantial heterogeneity in outcome definitions, denominators, and reporting formats. Qualitative variables were summarized as frequencies and percentages. Quantitative variables were reported as means or medians according to the distribution characteristics and the reporting format of the original studies included in this review. Due to the heterogeneity of study designs, interventions, and outcome reporting, formal meta‐analysis was not feasible, and descriptive summary measures were used. Subgroup analyses were interpreted descriptively, and reported p values were considered within the methodological limitations and heterogeneity of the included studies. Results A total of 82 articles with a total number of 748 patients were included in this study. Among these, 64 were case reports/case series, 14 were cohort studies (11 retrospective cohorts and 3 prospective studies), 2 were parallel randomized control studies, and 2 were single‐arm trials. A summary of findings is provided here based on therapeutic regimens. JAK Inhibitors Tofacitinib Tofacitinib twice a day was successfully used to control some severe flare‐ups in two patients with chronic bullous EM as well as a herpes‐associated EM. This treatment controlled the flare‐ups for a long period; however, tapering the medications evolved into a flare‐up, suggesting the need for lifelong tofacitinib [18, 19, 20]. In one study, a combination of tofacitinib and upadacitinib was successfully treated with recurrent EM; a titration dose was necessary [21]. Tofacitinib was generally administered twice daily; however, reported dosing regimens varied across studies, with commonly used doses in other clinical settings ranging from 5 mg to 10 mg twice daily. In the included cases, exact dosing was not consistently reported, reflecting variability in clinical practice [18, 19, 20, 21]. Ruxolitinib There was a complicated SJS case in which intravenous ruxolitinib was started followed by corticosteroid therapy. The treatment failed due to general deterioration i.e. worsening liver failure, acute kidney injury (AKI), and coagulopathies [22]. An 11‐year‐old pediatric patient with refractory T‐cell lymphoma, after receiving peripheral blood stem cell therapy, showed mucocutaneous manifestation and more than 80% body area involvement. Administration of steroids and IVIG failed to control the condition. A single dose of ruxolitinib was administered on day 9 which reversed the disease progression, and subsequent complete resolution of lesions on day 17 [23]. TNF Blockers Etanercept Etanercept has been used in many cases of TEN or SJS/TEN overlap syndrome (Table 2). In many cases, etanercept was tried due to failures in conventional therapies such as IVIG and corticosteroids. Mostly, a quick response to a single dose of etanercept was observed [24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40]. Etanercept was typically administered as a subcutaneous injection, most commonly at a dose of 50 mg per injection in reported cases, although dosing frequency and duration varied across studies [24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40]. A mean lag of 6.45 days between the onset of eruptions and etanercept therapy was reported and the average time for re‐epithelialization was 18 days. In some studies, patients received etanercept as first‐line therapy with a mean lag of 1.95 days of hypersensitivity reactions; complete resolution of lesions was reported after 14.15 days (mean) [41, 42, 43, 44, 45, 46, 47, 48, 49, 50]. The last group of patients were those who underwent a combined therapy of etanercept and other medications (i.e., corticosteroids, IVIG, and other immunomodulator agents); treatment was initiated within the first 3 days (mean: 1.33) and eruptions took an average of 14.16 days to re‐epithelialize [38, 51, 52, 53, 54, 55, 56]; two pediatric patients with 25% and 30% of body surface area involvement with a TEN‐like reaction showed improvement after a combination therapy of etanercept, systematic corticosteroids, IVIG, and cyclosporine [25, 57]. In an extreme case of a 25‐year‐old female with SJS, which was unresponsive to high doses of methylprednisolone and IVIG pulse, etanercept was initiated while the patient had almost 100% cutaneous involvement as well as severe agranulocytosis, thrombocytopenia, acute heart failure, pulmonary edema, and liver dysfunction. After 3 doses of etanercept, the lesions started to improve and a complete remission was reported within 4 months without any side effects. Also, a 13‐year‐old patient received etanercept after a 4‐day unsuccessful treatment with methylprednisolone and showed a complete resolution of eruptions in 13 days [34]. The reported cases were among the most severe reactions with up to 90% BSA involvement and a final resolution was achieved in many of them [31, 33]. Another notable report was a series of four pediatric patients with TEN, as young as 4 years old, initially managed with etanercept; in one of the patients, the initiation of etanercept therapy stopped the disease progression before the occurrence of histopathologic re‐epithelialization [58]. Despite successful therapeutic experiences, a case report in a patient who was under long‐term etanercept therapy for psoriasis flare‐ups showed no preventive effect with this medication and the patient eventually evolved TEN reaction [59]. Major complications were reported in two patients with several comorbidities and a TEN reaction involving more than 50% of their BSA who both eventually died of DIC and multi‐organ failure after adding etanercept to their prior corticosteroid regimens [32]. A single‐arm trial study evaluating the safety and efficacy of etanercept in 4 cases of SJS/TEN not responsive to steroids; despite the remarkable improvement, a patient developed sepsis that was hopefully cured with treatment. The mean time for re‐epithelialization was 13.5 days and the actual mortality rate was zero while a 12.1% mortality rate was predicted based on the patient's SCORTENs [37]. In a case series of three patients with TEN by Faris, all of the patients eventually passed away after adding etanercept to cyclosporine. The main reason for death was reported as electrolyte imbalance, AKI, and systemic inflammatory response syndrome (SIRS) in case one; atrial fibrillation (AF) and fetal bleeding in case two; cardiac arrest in case three. It was reported that adding etanercept to other immunosuppressives such as corticosteroids or cyclosporine may be associated with an increased risk of complications, including infections, although the available evidence remains limited and inconclusive [33]. Nine Cohort studies compared the effect of etanercept to conventional medications in treating hypersensitivity reactions; Details of these studies can be found in Table 3. Pham et al., 2019 showed that there is no significant difference in mortality rates, length of hospitalization (LOS), length of intensive care unit (ICU) admission, or infection rate between combined etanercept‐treated and non‐etanercept treated groups; however, the former group tended to experience a longer delay in response to the treatment [60]. Meanwhile, other studies showed a significant difference due to shorter LOS in the group of patients under etanercept therapy [61, 62, 63, 64, 65, 66]. Warwick et al., 2011 studied the effect of etanercept on 9 patients with SJS and compared the results to 21 patients receiving traditional treatments. The final report showed a lower mortality rate in etanercept group (0.00 vs. 30%) [67]. In another cohort study, Ao ST et al., 2022 concluded that compared to steroid monotherapy, combination therapy with etanercept significantly shortened the course of initial steroid therapy and the duration of the acute stage [66]. Dreyer et al., 2021 also reported that the most effective use of etanercept would be achieved when the treatment is started earlier compared to those receiving IVIG and/or steroids before etanercept [68]. Worswick et al., 2020 compared the mortality rates between patients treated with etanercept after failure of corticosteroid therapy with patients treated with etanercept as an initial therapy in a retrospective cohort study. Results showed a lower mortality rate in the first group (zero actual deaths vs 17.5% expected mortality rate in the second group and 20.8% vs 33% predicted mortality in the first group). Also, in another study by Didona et al., 2019 etanercept led to a significant reduction in actual mortality rate in TEN/SJS patients compared to their SCORTEN‐based expected mortality [61]. Wang et al., 2018 designed a randomized control trial on etanercept for patients with SJS/TEN spectrum in 2018 to compare etanercept with corticosteroid. 93 patients were enrolled in this study and were randomly allocated to either etanercept or corticosteroids group. Results of this study showed a decreased mortality rate based on the SCORTEN prediction model (8.3% vs. 17.7) and, a shorter healing time of the eruptions (median 14 days vs. 19 days in the corticosteroids group). Meanwhile, a lower rate of gastrointestinal hemorrhage as one of the disease complications was observed in the etanercept group (2.6% vs. 18.2% in the corticosteroids group) [69]. Regarding the safety and efficacy of etanercept plus corticosteroids compared to corticosteroid monotherapy, Zhang et al., 2022 conducted a comparative retrospective cohort. Results showed a reduction in the standard mortality rate and actual mortality rate as well as a shorter healing time of the lesions and lower rates of gastrointestinal adverse events in the combination group [65]. In a multi‐center single‐arm trial study designed by Oginezawa et al., 2023, etanercept was used in a group of patients resistant to corticosteroids. The patients in this trial had a mean recovery time of 3.5 days and a mean re‐epithelialization time of 13.5 days. One patient eventually expired due to severe sepsis despite being on etanercept treatment [37]. Besides SJS and TEN, Etanercept was also used in some cases of EM major (Table 4). In one study an EM major reaction developed after H. Pylori therapy in a 73‐year‐old woman. The initial SCORTEN was 2 with an 80% of body surface involvement. Due to active gastric ulcer and gastrointestinal bleeding, the use of corticosteroids was postponed and 6 doses of etanercept injection were used followed by some unsuccessful conservative therapies such as compound glycyrrhizin. A rapid response without any side effects was reported in this case and a complete remission of lesions was reported on day 14 [70]. Another case was a 45‐year‐old man (with no past medical history) with a severe form of EM who was unresponsive to methylprednisolone. Etanercept was added to the treatment regimen 5 days after symptoms onset; a complete epithelialization was reported 2 days after etanercept therapy [35]. Also, etanercept was tried as a first‐line therapy for a 5‐year‐old pediatric patient with an atypical form of EM major which resulted in a complete remission without any side effects [71]. For etanercept, the reported subgroup‐level re‐epithelialization times were 18 days in cases treated after failure of conventional therapies, 14.15 days in first‐line therapy studies, and 14.16 days in combination‐therapy studies, corresponding to a crude average of approximately 15.4 days across these summarized subgroups. In EM major cases treated with etanercept, re‐epithelialization time was reported in two cases (2 and 14 days), yielding a crude mean of 8 days. For infliximab, the average re‐epithelialization time reported in the included studies was 16.6 days for monotherapy and 14.4 days for combination therapy. Adalimumab In a study, after noticing that a 6‐year‐old pediatric patient with SJS was unresponsive to a combined regimen of corticosteroids and human immunoglobin, two IV doses of adalimumab were added to the prior regimen. Despite the 11‐day lag between adalimumab therapy and the onset of rashes, a gradual resolution in cutaneous manifestations was observed [72]. Two other studies respectively reported 70‐ and 60‐year‐old patients with TEN, involving nearly 70% of their BSA, following the treatment for metastatic gastric malignancy and unresectable hepatocellular carcinoma. Both of the patients experienced disease progression despite the use of high‐dose systemic corticosteroids and IVIG treatment. The initial SCORTEN for one of these patients was calculated 5, further administration of adalimumab led to satisfactory results including faster lesion healing, reduction in duration of the treatment, and complete resolution of lesions by the end of hospitalization [73, 74]. In a retrospective chart review by Kherlopian et al., 2022 on SJS/TEN patients treated with adalimumab between 2017 and 2021 in Australia, all of these patients experienced a fairly prompt resolution of lesions without any adverse effects. Furthermore, they showed a shorter LOS (22.5 days vs 33 days in those who received non‐TNF‐α immunosuppressants such as glucocorticoids, IVIG, and cyclosporine) [75]. Furthermore, Gong et al., 2023 conducted two clinical cohorts on SJS/TEN to compare and analyze the efficacy and safety of adalimumab in combination with methylprednisolone versus monotherapy with methylprednisolone. This study showed that combination therapy remarkably shortened the time of mucocutaneous re‐epithelialization and healing compared to conventional therapy [76]. Adalimumab was also used to treat recurrent EM as a trial. The condition lasted for 2 years and was poorly controlled with daily doses of prednisolone. Scheduled doses of IV adalimumab (every other week) could suppress the active lesions and control the disease flare‐ups over time [77]. Adalimumab was administered as subcutaneous injections, typically following standard dosing regimens used in other inflammatory conditions (e.g., 40 mg), although variations were observed across studies [72, 73, 74, 75, 76, 77]. Infliximab Infliximab is a member TNF‐alpha blocker family. The efficacy and safety of infliximab in the treatment of TEN or SJS/TEN overlap syndrome have been investigated in several studies. The different characteristics of 17 case reports with a total of 23 participants are described in Tables 4 and 5. Each identified study was classified as either biologic monotherapy or combination therapy (Table 5). As shown in Table 4, in many of these studies monotherapy treatment with Infliximab was performed following the failure of primary therapeutic modalities (methylprednisolone, IVIG, and oral prednisolone) [12, 15, 40, 78, 79, 80, 81, 82, 83]. Other reports studied the efficacy and safety of infliximab in combination with other systemic therapies, as demonstrated in Table 6. Infliximab was commonly administered as a single intravenous dose of 5 mg/kg, with some studies reporting repeated dosing depending on clinical response [12, 15, 40, 78, 79, 80, 81, 82, 83]. In 2002, the first case of effective treatment of TEN with Infliximab, with a re‐epithelialization duration of 4 weeks was reported; A rapid increase in the spread of the lesions ceased and no new lesions formed within the following days of the treatment initiation [84]. In two other studies, Hunger et al., 2005 and Al Shouli et al., 2005 reported that patients with TEN and other systemic comorbidities benefit from infliximab and most of the damaged skin was rapidly covered by a new epidermis [12, 85]. Additionally, Meiss et al., 2007 proved that infliximab can be an effective therapeutic measure in treating TEN overlapped with acute generalized exanthematous pustulosis [86]. In patients with a high percentage of skin involvement, BSA ≥ 80%, infliximab resulted in a satisfactory effect [15, 81]; however, there was a 9‐day lag between the onset of eruptions and infliximab therapy in one of the studies [15]. In infliximab monotherapy, the lag between the onset of eruptions and infliximab therapy was between 3 and 9 days in some cases [12, 15, 80, 87, 88]. Among pediatric participants, the effectiveness and rapid response of infliximab (less than 2 weeks) are reported [78, 87, 89]. Another pediatric case was reported by Lootah et al., 2023, about a 10‐year‐old pediatric patient with no known past medical history who was diagnosed with SJS with BSA > 90% and spared perineal region; after an unsuccessful course of IVIG and methylprednisolone pulse, infliximab was started and resulted in a rapid improvement and discharge after 5 days. In a follow‐up visit after 2 weeks, the primary skin lesions were fully resolved [90]. Most studies have indicated that a single dose of 5 mg/kg infliximab can result in a complete and irreversible recovery in both adults and children suffering from TEN; however, Jiang et al., 2018 reported a case in which the patient achieved a complete recovery with two doses of 4 mg/kg infliximab [88]. In most studies, re‐epithelialization of the skin occurred after 1–2 weeks, while in some cases it happened after 28–35 days and a complete resolution of eruptions was also achieved after a longer period [79, 83, 84, 91]. The average number of days for re‐epithelialization was 16.6 days in monotherapy and 14.4 days in the combination therapy group. Regarding Side effects, Gaitanis et al., 2012 reported an elderly case suffering from multiple comorbidities such as AF, benign prostatic hyperplasia (BPH), hypertension (HTN), and heart failure who eventually passed away from sepsis and multi‐organs failure despite being on a therapeutic regimen of high‐dose corticosteroids, IVIG, and infliximab [92]. Bacteremia and pulmonary thromboembolism (PTE) were also reported in two cases by Zarate; however, they were managed successfully without any further complications [81]. Paquet et al., 2014 also designed a randomized controlled trial on 10 confirmed SJS patients who were randomly allocated to either N‐acetylcysteine monotherapy or N‐acetylcysteine plus infliximab therapy; a higher rate of mortality (2 cases, 40%) was observed in the combination therapy group compared to the predicted mortality rate based on SCORTEN (21.4%) and the mortality rate in the control group (20%). All of these mortalities were due to multi‐organ failure and septicemia [93]. However, these adverse events were not reported to be linked to medication administration. Other Medications Thalidomide/Lenalidomide Thalidomide and lenalidomide, although not classified as TNF‐α or JAK inhibitors, have been explored as immunomodulatory agents in selected cases and are therefore discussed as adjunctive therapeutic options. Thalidomide is an immunomodulatory drug (ImiD) that is an effective treatment for EM; however, long‐term use is often limited due to adverse effects. Some studies have evaluated the effectiveness of ImiDs on EM (persistent and recurrent form) [94, 95, 96, 97, 98, 99, 100] (Table 7). A retrospective cohort studied the treatment of thalidomide in 35 patients with chronic EM. The results were associated with complete remission after 6 months in two‐thirds of patients. The main adverse effects were asthenia and neuropathy, which led to the discontinuation of the treatment in some patients [94]. Neurological side effects of thalidomide in the treatment of EM were reported in other studies as well; Moisson et al., 1992, found that in combination therapy with thalidomide and other medications such as steroids, acyclovir, hydroxychloroquine, dapsone, high‐dose IVIG, and colchicine abnormality in EMG and neuropathy were detected. Additionally, therapy was effective only on the oral lesions in one of the patients [99]. The number of studies conducted on children was insufficient to prove the efficacy of thalidomide among the pediatric population, although Chen et al., 2008 has confirmed complete remission in a 15‐year‐old male patient with persistent EM [96]. Another study has suggested cautious use of thalidomide in patients with coexisting psoriasis. Thalidomide 100 mg daily was introduced for a 41‐year‐old woman and effectively controlled the EM eruptions, however, the exacerbation of psoriasis led to cessation of thalidomide after 2 weeks [97]. Recurrent EM was also successfully managed by thalidomide. In this condition, maintenance therapy with a lower dose of thalidomide was able to control flare‐ups without complications [98, 100]. Lenalidomide is a thalidomide analog which showed a better tolerability profile compared to thalidomide. Drahy et al., 2018, reported three female patients with chronic EM for 7–18 years with unsuccessful treatment with valacyclovir and thalidomide. For all three patients, treatment with lenalidomide was initiated at the dose of 10 mg/d for 21 days. One patient experienced a relapse, requiring dose adjustment which led to partial remission. Other patients showed complete remission after 1 month of treatment with no complications [95]. Recombinant Medications There were two studies to investigate the effect of recombinant human tumor necrosis factor‐α receptor: IgG Fc fusion protein in the treatment of TEN and SJS. A case report by Lu et al., 2020, showed successful treatment in an SJS patient resistant to glucocorticoids. Furthermore, another study on 22 patients with TEN revealed a successful response with no recurrence/complication, and eventually most skin lesions subsided after 2 weeks of therapy [101, 102]. Discussion This study summarizes findings from 82 articles with a total of 748 patients on the therapeutic regimens used in patients with SCARs, such as SJS, TEN, and EM major. Two main groups of drugs were examined: JAK inhibitors and TNF‐α blockers. The findings of this systematic review are consistent with previous reports suggesting a potential role for targeted immunomodulatory therapies, particularly TNF‐α inhibitors, in modifying the disease course of SCARs. Several studies have indicated that TNF‐α blockade may contribute to rapid cessation of disease progression and accelerated re‐epithelialization. However, the current body of evidence is largely derived from case reports, case series, and observational studies, which limits the strength of conclusions and highlights the need for well‐designed randomized controlled trials [24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 72]. Current clinical guidelines emphasize supportive care as the cornerstone of management for SJS/TEN, including fluid replacement, wound care, and infection control. The role of systemic therapies such as corticosteroids, cyclosporine, and intravenous immunoglobulin (IVIG) remains controversial due to inconsistent evidence regarding their efficacy and safety [1, 5, 23]. In this context, emerging therapies such as TNF‐α inhibitors and JAK inhibitors have attracted increasing attention as potential alternatives, although robust evidence supporting their routine use is still lacking. Regarding JAK inhibitor drugs, tofacitinib was successfully used to control severe flare‐ups in two cases of chronic bullous EM and a herpes‐associated EM, but long‐term usage was required, as tapering the drug led to flare‐ups [12, 13, 14]. In contrast, intravenous ruxolitinib did not improve the general instability conditions in a complicated SJS case, and general deterioration continued even after the use of ruxolitinib, and finally, the patient passed away [22]. TNF‐α blockers were found to be more effective in treating SCARs. The most common drug among those considered in this review is etanercept which has been used in many cases of SJS/TEN spectrum. Etanercept has been used in cases where conventional therapies such as IVIG and corticosteroids have failed. In most cases, patients showed a rapid response to a single dose of etanercept, and a deterioration in cutaneous reactions was observed [24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 57]. The average time for re‐epithelialization was 14.71 days. However, there were cases where etanercept was used as the first‐line treatment after hypersensitivity reactions, and the duration of the complete resolution was 16.58 days. There were also cases where etanercept was used in combination with other drugs (i.e., corticosteroids, IVIG, and other immunomodulator agents), and treatment was started within the first 2 days, taking an average of 15.40 days for eruptions to re‐epithelialize [41, 42, 43, 44, 45, 46, 47, 48, 49]. An adolescent case of 13 years old who received etanercept followed by a 4‐day unsuccessful treatment with methylprednisolone showed complete resolution of eruptions in 13 days [34]. The most severe reactions were reported in four cases with up to 90% BSA involvement, and all achieved final resolution [31, 33]. The only major side effect observed was in a patient with several comorbidities and a TEN involving 60% of BSA who eventually died of DIC after adding etanercept to his prior corticosteroids regimen [32]. Some temporary complications, such as electrolyte imbalance, Acute kidney injury, cardiac arrest, and septicemia in four cases were managed promptly, and all patients achieved complete re‐epithelialization under 30 days [33]. Eight cohort studies comparing etanercept to conventional regimens for hypersensitive reactions were included in the manuscript. Except for one of those which showed no significant difference in mortality rate, LOS, ICU admission, and infectious rate (despite the delayed onset of etanercept therapy), other studies indicated shorter hospitalization periods for the patients receiving etanercept [61, 62, 63, 64, 65]. Warwick's study on 9 SJS patients receiving etanercept showed a lower mortality rate compared to traditional treatments (0.00 vs. 30%) [67]. Ao.S.T.'s study concluded that combination therapy with etanercept significantly shortened the course of the initial steroid treatment and the duration of the acute stage compared to steroid monotherapy [66]. Dreyer's study showed that the most prominent effects of using etanercept would be observed in cases where treatment is started quickly, as opposed to those where IVIG and/or steroids are given before etanercept [68]. Adalimumab was also used in a pediatric patient with SJS, who was unresponsive to a combined regimen of corticosteroids and IVIG, and in a case of recurrent EM that had been poorly controlled with daily doses of prednisolone as a trial. In both cases, a gradual resolution in cutaneous manifestations was observed [73]. Several studies have investigated the effectiveness and safety of Infliximab, another TNF‐alpha blocker, in treating TEN or SJS/TEN overlap syndrome. Fifteen case‐report studies with a total of 21 participants were identified and classified as either biologic monotherapy or combination therapy. Monotherapy with Infliximab was performed in many of these studies after the failure of primary therapeutic modalities [12, 15, 40, 78, 79, 80, 81], and combination therapy was used in other studies. The average number of days to re‐epithelialization was 16.6 days and 14.4 days for monotherapy and combination therapy groups respectively [12, 15, 78, 80, 87, 89]. Among the reviewed articles, three studies mentioned the effectiveness and rapid response of this drug in less than 2 weeks in the treatment of pediatric participants [78, 87, 89]. In 2002, the first case of effective treatment of TEN with Infliximab, with a re‐epithelialization duration of 4 weeks, was reported [84]. Hunger et al., 2005 and Al Shouli et al., 2005 showed that patients with comorbidities also benefit from Infliximab [12, 85]. Meiss, 2007 showed its effectiveness in the overlap of TEN and acute generalized exanthematous pustulosis by reporting 3 cases [86]. Infliximab had a satisfactory effect on BSA ≥ 80% [15, 81], although there was a 9‐day lag between the onset of eruptions and Infliximab Therapy in some cases [15]. Re‐epithelialization occurred between 1 and 2 weeks in most studies, while some reported longer durations with dermatological follow‐up revealing the resolution of eruptions after a long time [79, 83, 84, 91]. Thalidomide and lenalidomide, although not classified as TNF‐α or JAK inhibitors, have been explored as immunomodulatory agents in selected cases and are therefore discussed as adjunctive therapeutic options. Thalidomide, as another immunomodulatory drug, has shown efficacy in the treatment of EM, a hypersensitivity skin condition involving T‐cell and B‐cell responses, when antiviral therapy fails. The effectiveness of thalidomide on persistent and recurrent forms of EM has been evaluated in a limited number of articles [63], with a recent retrospective cohort study in 2019 on 35 patients reporting complete remission after 6 months in two‐thirds of patients, although some patients discontinued treatment due to adverse effects such as asthenia and neuropathy [63]. Neurological side effects have been reported in other studies when thalidomide was used in combination therapy with other drugs [68]. Studies in pediatric populations are insufficient to prove the efficacy of thalidomide, although a single study reported complete remission in a 15‐year‐old male [65]. Cautious use of thalidomide is recommended in patients with coexisting psoriasis [66]. Lenalidomide is a thalidomide analog and, as its alternative shows a better tolerability profile than thalidomide. Drahy et al., 2018 reported three women with chronic EM were treated with Lenalidomide 10 mg/d from Day 1 to Day 21 of a 28‐day cycle. One patient experienced a relapse, while the other two achieved complete remission after 1 month of treatment [64]. Two other studies found that 22 patients with TEN had an effective response to recombinant human tumor necrosis factor‐α receptor with most skin lesions subsiding after 2 weeks without recurrence or complications [101, 102]. From a clinical perspective, these findings suggest that TNF‐α inhibitors and JAK inhibitors may be considered as adjunctive therapeutic options, particularly in severe or refractory cases of SCARs. However, treatment decisions should be individualized, taking into account disease severity, comorbidities, and the potential risks associated with immunosuppression. The heterogeneity of the included studies, including variations in study design, patient populations, treatment regimens, and outcome reporting, represents a major challenge in interpreting the available data. Additionally, the predominance of case‐based evidence introduces potential reporting and selection biases. Despite these limitations, a consistent trend toward favorable clinical outcomes, such as reduced disease progression and shorter re‐epithelialization time, was observed across multiple studies, suggesting a potential therapeutic benefit of targeted immunomodulation. The methodological quality of the included studies varied depending on the study design. The majority of included studies were case reports and case series, which inherently have lower levels of evidence and are subject to reporting bias. Cohort studies demonstrated moderate quality, although most were retrospective in nature and susceptible to selection bias. The limited number of randomized controlled trials showed moderate methodological quality but were constrained by small sample sizes. Overall, heterogeneity in study design and methodological limitations should be considered when interpreting the findings (Table 8). Table 8Study‐by‐study draft quality assessment.Author, yearTherapyStudy design N Assessment toolDraft gradeRationaleNatsis, 2022EtanerceptCase report1NIH + MuradFairSingle‐patient report with outcome details; limited external validity and no comparator.Ridha, 2021EtanerceptCase report1NIH + MuradFairAdequate clinical detail and short‐term outcome; single case and no control group.Faris, 2021EtanerceptCase series3NIH + MuradFairSmall series with clinically important outcomes; high risk of selection/reporting bias.Famularo, 2007EtanerceptCase report1NIH + MuradFairCase adequately described but limited by single‐patient design and confounding co‐therapies.Sadighha, 2009EtanerceptCase report1NIH + MuradFairBasic treatment‐outcome sequence reported; limited methodological depth.Didona, 2015EtanerceptCase seriesNANIH + MuradFairSeries‐level outcome reporting present; details of patient selection and comparability limited.Paradisi, 2014EtanerceptCase series10NIH + MuradGoodRelatively larger case series with multiple patient‐level outcomes; still uncontrolled.Yardanova, 2022EtanerceptCase report1NIH + MuradFairUseful clinical description but single case with limited generalizability.Paradisi, 2020EtanerceptCase seriesNANIH + MuradFairReports aggregated outcomes and expected‐vs‐observed mortality; still uncontrolled.Gavigan, 2018EtanerceptCase report1NIH + MuradFairPediatric case with treatment chronology; no comparator and limited follow‐up detail.Didona, 2019EtanerceptRetrospective cohort30Newcastle‐Ottawa ScaleModerateComparative mortality analysis reported, but likely retrospective and prone to confounding.Sivagnanalingam, 2022EtanerceptRetrospective cohort24Newcastle‐Ottawa ScaleModerateComparative data available, but sample remains limited and selection bias likely.C.H. Pham, 2019EtanerceptRetrospective cohort13Newcastle‐Ottawa ScaleModerateComparator present and multiple outcomes assessed; small sample and treatment delay imbalance.Tian, 2022EtanerceptRetrospective cohort25Newcastle‐Ottawa ScaleModerateComparative length‐of‐stay data available; likely retrospective and subject to confounding.Dreyer, 2021EtanerceptRetrospective cohort22Newcastle‐Ottawa ScaleModerateComparator included and outcomes reported, but nonrandomized treatment allocation limits inference.Worswick, 2020EtanerceptRetrospective cohort30Newcastle‐Ottawa ScaleModerateMortality comparison provided; residual confounding and case‐mix differences remain concerns.Pham, 2018EtanerceptRetrospective cohort13Newcastle‐Ottawa ScaleModerateReports ICU/LOS/infection outcomes with controls, but very small sample.S. T. Ao, 2022EtanerceptRetrospective cohort25Newcastle‐Ottawa ScaleModerateDirect comparison to steroid monotherapy strengthens evidence, but nonrandomized design limits certainty.Wang, 2018EtanerceptRandomized controlled trial96Cochrane RoBModerateRandomized design improves validity; still limited by sample size and possible trial‐level concerns.Oginezawa, 2023EtanerceptSingle‐arm trial4NIH/descriptive assessmentFairProspective treatment data but no control arm and very small sample.Zhang, 2022EtanerceptRetrospective cohort242Newcastle‐Ottawa ScaleHighLarge comparative cohort with multiple outcomes; still observational with potential residual confounding.Trujillo‐Trujillo, 2018Etanercept (EM major)Case report1NIH + MuradFairSingle severe EM case with response data; uncontrolled.Ling, 2017Etanercept (EM major)Case report1NIH + MuradFairDetailed response timeline reported, but single‐patient evidence only.Huang, 2023Etanercept (EM major)Case report1NIH + MuradFairPediatric case with treatment chronology; limited external validity.Hunger, 2005InfliximabCase report1NIH + MuradFairAdequate clinical narrative and outcome, but single case.Wojtkiewicz, 2008InfliximabCase report1NIH + MuradFairTreatment and recovery described; no comparator.Scott‐Lang, 2011InfliximabCase report1NIH + MuradFairPediatric case adds value but remains anecdotal evidence.Worsnop, 2012InfliximabCase report1NIH + MuradFairReasonable case detail; limited generalizability.Wallenborn, 2017InfliximabCase report1NIH + MuradFairDocuments recovery after prior therapy; confounding co‐treatment present.Al‐Shouli, 2005InfliximabCase report1NIH + MuradFairCase described with key outcomes; still uncontrolled.Seminario‐Vidal, 2017InfliximabCase report1NIH + MuradPoorImportant outcome reported, but substantial missing baseline and timing details.Zarate, 2013InfliximabCase series2NIH + MuradFairSmall series with adverse events and recovery reported; no control arm.Chafranska, 2019InfliximabCase report1NIH + MuradFairPediatric case with outcome details; limited methodological strength.Kreft, 2010InfliximabCase report1NIH + MuradFairClinical response reported but uncontrolled and prone to publication bias.Fischer, 2002InfliximabCase report1NIH + MuradFairHistorically important case; single‐patient evidence only.Meiss, 2007InfliximabCase series3NIH + MuradFairSmall series with favorable outcomes; combination therapy complicates attribution.Kreft, 2014InfliximabCase report1NIH + MuradFairClear treatment timeline with prior IVIG; no comparator.Jiang, 2018InfliximabCase report1NIH + MuradFairAdequate case‐level detail and recovery time; single case.Plant, 2020InfliximabCase report1NIH + MuradPoorOutcome mentioned but incomplete quantitative detail limits appraisal.Gaitanis, 2012InfliximabCase series3NIH + MuradFairSeries includes major adverse event data; very small and confounded by co‐therapies.Konda, 2022TofacitinibCase report1NIH + MuradFairGood longitudinal follow‐up, but single case with extensive prior therapy.Csiky‐Sessoms, 2019TofacitinibCase report1NIH + MuradFairUseful relapse information after discontinuation; anecdotal evidence.Damsky, 2016TofacitinibCase report1NIH + MuradFairDetailed refractory disease history, but no comparator.Murphy, 2021Tofacitinib/UpadacitinibCase series4NIH + MuradFairMulti‐patient report with dose titration details; uncontrolled.Drahy, 2018LenalidomideCase series3NIH + MuradFairSmall series with response heterogeneity; no control group.Chen, 2008ThalidomideCase report1NIH + MuradFairStraightforward clinical response reported; single case.Moisson, 1992ThalidomideCase series2NIH + MuradFairIncludes adverse effects and mixed efficacy, but very small and uncontrolled.Bahmer, 1982ThalidomideCase report1NIH + MuradPoorOlder report with limited methodological/reporting detail.Cherouati, 1996ThalidomideCase series26NIH + MuradGoodLarger case series with maintenance‐response data; still uncontrolled and vulnerable to bias.Varma, 2006ThalidomideCase report1NIH + MuradFairCaptures clinically relevant adverse outcome; single‐patient evidence.Roux, 2021ThalidomideRetrospective cohort35Newcastle‐Ottawa ScaleModerateLargest chronic EM dataset, but retrospective observational design limits causal inference.Baillis, 2017AdalimumabCase report1NIH + MuradFairSingle recurrent EM case with follow‐up; uncontrolled. Study‐by‐study draft quality assessment. Conclusion Based on the available evidence, TNF‐α blockers and JAK inhibitors may represent promising therapeutic options, particularly in patients with severe or rapidly progressive SCARs, as well as in cases refractory to conventional treatments. These agents may be associated with faster disease control and improved clinical outcomes in selected patients. However, given the heterogeneity and limited quality of the available data, these findings should be interpreted with caution, and further high‐quality studies are required to better define the optimal target populations and treatment strategies. Limitation and Recommendation Several limitations should be considered when interpreting the findings of this study. First, the majority of included studies were case reports and case series, which represent a low level of evidence and are inherently subject to reporting and selection biases. Second, the potential for publication bias cannot be excluded, as studies with positive outcomes are more likely to be published, particularly in the context of rare and severe conditions such as SCARs. Third, substantial heterogeneity existed across studies in terms of patient populations, treatment regimens, and outcome definitions, which limits comparability. Finally, a formal analysis of dose‐response relationships was not feasible due to inconsistent and incomplete reporting of dosing data across the included studies. Author Contributions Sadaf Salehi: conceptualization, investigation. Pooneh Torabi: writing – original draft, methodology. Mahsa Abbaspour: validation, visualization. Nima Hajizadeh: writing – review and editing, software. Sara Sadeghi: writing – review and editing, writing – original draft. Alireza Jafarzadeh: supervision, project administration. Azadeh Goodarzi: supervision, project administration, visualization. Ethics Statement An ethics statement is not applicable because this study is based exclusively on published literature. Conflicts of Interest The authors declare no conflicts of interest. Transparency Statement The Azadeh Goodarzi affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained. Acknowledgments The authors would like to express their gratitude to the authorities of Hazrat Fatemeh Hospital for their technical assistance. No artificial intelligence (AI) tools were used in the preparation of this manuscript. Contributor Information Alireza Jafarzadeh, Email: alirezajafarzadeh8@gmail.com. Azadeh Goodarzi, Email: azadeh_goodarzi1984@yahoo.com, Email: goodarzi.a@iums.ac.ir. Data Availability Statement All data produced in the present study are available upon reasonable request to the authors. References Associated Data Data Availability Statement All data produced in the present study are available upon reasonable request to the authors.